YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Merck Acquires Cancer Drug Rights


April 17, 2012 | Merck has acquired the rights to an Endocyte cancer drug candidate for $120 million and up to $880 million in milestone payments, the companies announced yesterday. Endocyte shares rose 101% after the announcement. Reuters
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.